Merck & Co Inc
NYSE: MRK
$96.31
-$2.05 (-2.1%)
Closing Price on November 15, 2024
MRK Articles
The 30-Year Treasury auction, the so-called Long Bond, had a strong participation for what is technically a 29-year and 11-month bond. The participation rate was strong enough that this still shows...
Published:
Last Updated:
Financial markets have been reeling as investors grow more concerned about the economy: An S&P downgrade of the full faith and credit of the United States, dismal GDP data, and ongoing weak...
Published:
Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability. One way to make up for the loss is to get US Food & Drug...
Published:
Merck & Co. Inc. (NYSE: MRK) released second-quarter results last Friday and Pfizer Inc. (NYSE: PFE) reported this morning. The results of both drug behemoths are largely in line with analysts...
Published:
Merck (NYSE: MRK) released an unusual earnings announcement. It is profitable, has a bright future, and will fire about 13,000 people. These employees can leave with the knowledge that they have...
Published:
Earnings season is in full throttle and many major companies are due to report in the week ahead. Some of the key reports we are featuring for detailed earnings previews are the following: Baidu,...
Published:
Last Updated:
Many drug companies face a what is called a patent cliff ahead, where the Big Pharma players will have key drugs go off-patent and there will be new generic competition. While this is a challenge...
Published:
No industry was able to avoid short selling activity, particularly among its largest companies. Tech, automotive, conglomerates, consumer goods, and financial shares were all under pressure, and big...
Published:
Now that the 10-Year Treasury Note has been back to close to the 3.00% yields again, we wanted to see which Dow Jones Industrial Average components had a higher dividend yield than the 10-Year...
Published:
Last Updated:
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Tuesday morning. Alkermes, Inc. (NASDAQ: ALKS) Raised to Outperform at Leerink Swann....
Published:
Last Updated:
The drug sector has become rather boring and investors already know all about the ongoing patent expiration threats that loom in the industry. The good news is that the drug sector does still offer...
Published:
Last Updated:
It is time for “The Daily Dividend” and we have an interesting call ahead. How long has it been that Amgen Inc. (NASDAQ: AMGN) has been touted as a “Should Be” dividend stock? Too...
Published:
Last Updated:
Yahoo! (NASDAQ: YHOO) is in talks to sell its part of a Japanese joint venture for $8 billion. (Reuters) Apple (NASDAQ: AAPL) will release its iPad 2 today. (Reuters) The SEC charged a former Goldman...
Published:
Media reports questioning whether the United States will keep its “Triple-A Rating” in the future are frequent. The fear of endless budget deficit spending and quantitative easing have only...
Published:
Last Updated:
Companies locked in a struggle to remain viable and maintain their profits and sales sometimes begin to run out of customers. This happened to GM (NYSE: GM), which had a 50% share of domestic car...
Published:
Last Updated: